Lifelong Management of Hypertension
H. Mitchell Perry Jr.
แแแ. 2012 ยท Developments in Cardiovascular Medicine แฌแแแแ 26 ยท Springer Science & Business Media
แแแฌแแแแ
268
แแแแ แแ
reportแ แแแขแแแแแแ แแ แแแแแฎแแแแแแ แแแฃแแแกแขแฃแ แแแแแแ ย แจแแแขแงแแแ แแแขแ
แแ แแแฌแแแแแก แจแแกแแฎแแ
In the thirty years since the advent of efTective pharmacologic treatment for hypertension, the world ofthe hypertensive has been transformed beyond recog nition. The first change involved only malignant hypertensives with enough residual renal parenchyma to survive. Such a hypertensive could trade inevitable renal failure - unless an intracerebral bleed occurred first - for a rigid regimen which prevented his blood pressure from destroying him but which was asso ciated with nearly intolerable side effects. Over the next 20 years, increasing numbers of patients with hypertension of decreasing severity were treated with drugs that had fewer and fewer side effects. In 1970, with the medical world finally ready to accept the concept, the well-known Veterans Administration Study demonstrated that morbidity and mortality could be diminished in mode rately hypertensive patients by antihypertensive therapy that had minimal side effects. As a result there has been a major attempt to bring everyone with elevated blood pressure under lifelong pharmacologic control. It is difficult, however, to know what levels ofblood pressure deserve treatment; many who, when therapy first became available, would not have even been considered hypertensive are now candidates for treatment. The lower the pressure, the larger the potential population to be treated, but the smaller the individual risk and hence the smaller the possible benefit. The point where decades of diminished quaiity of life from treatment begins to outweigh a possible late-life complication is yet to be de termined.
แจแแแคแแกแแ แแก แแแฌแแแแ
แแแแแฎแแ แแ แแฅแแแแ แแแ แ.
แแแคแแ แแแชแแ แฌแแแแแฎแแแกแแแ แแแแแแจแแ แแแแ
แกแแแ แขแคแแแแแ แแ แขแแแแแขแแแ
แแแแแแกแขแแแแ แแ Google Play Books แแแ Android แแ iPad/iPhone แแแฌแงแแแแแแแแแแกแแแแก. แแก แแแขแแแแขแฃแ แแ แแแแแฎแแ แชแแแแแแก แกแแแฅแ แแแแแแชแแแก แแฅแแแแก แแแแแ แแจแแแ แแ แกแแจแฃแแแแแแก แแแแชแแแ, แฌแแแแแแฎแแ แกแแกแฃแ แแแแ แแแแขแแแขแ แแแแแกแแแแ แแแแแแแก, แ แแแแ แช แแแแแแ, แแกแ แฎแแแแแ แแจแ แ แแแแแจแ.
แแแแขแแแแแ แแ แแแแแแฃแขแแ แแแ
Google Play-แจแ แจแแซแแแแแ แแฃแแแแฌแแแแแแแก แแแกแแแแ แแฅแแแแ แแแแแแฃแขแแ แแก แแแ-แแ แแฃแแแ แแก แแแแแงแแแแแแ แจแแแแซแแแแ.
แแแฌแแแแแแฎแแแแแแ แแ แกแฎแแ แแแฌแงแแแแแแแแแ
แแแแฅแขแ แแแฃแแ แแแแแแก แแแฌแงแแแแแแแแแแ แฌแแกแแแแแฎแแ, แ แแแแ แแชแแ Kobo eReaders, แแฅแแแ แฃแแแ แฉแแแแขแแแ แแแ แคแแแแ แแ แแแแแแขแแแแ แแแ แแฅแแแแก แแแฌแงแแแแแแแแจแ. แแแฎแแแ แแแแก แชแแแขแ แแก แแแขแแแฃแ แ แแแกแขแ แฃแฅแชแแแแแก แแแฎแแแแแ แแแแแแขแแแแ แคแแแแแแ แแฎแแ แแแญแแ แแ แแแฌแแแแแแฎแแแแแแแ.
